French drug major Sanofi plans to introduce new drugs and enhance localisation while expanding the reach of its existing brands in tie-up with domestic drug companies. The firm plans to strengthen its presence in the diabetes segment, and grow its consumer healthcare business, incorporating local production of its various products in India.

Sanofi India has embarked on a mission to prepare for an accelerated growth path in the country, where it sees significant opportunity. Backed by its focus on diabetes, the company will continue to cater to therapies for diabetes in India. With Soliqua, the company will enter into the premix insulin segment allowing for more tailored options in diabetes management.

Sanofi has a pipeline of 12 different products lined up for launch in the country. The company plans to introduce Dupixent, the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults, in the country. Other products in the pipeline for the Indian market. include Xenpozyme, Nexviazyme, Beyfortus and Rezurock. The company works with 15 contract manufacturing entities in the country. Besides, it also has its own manufacturing footprint in Goa.

Sanofi Healthcare India has partnered with Cipla, Dr Reddy's Laboratories and Emcure to ehance the reach of its products in the country.